SCHEMBL1765895

SCHEMBL1765895

Cc1cc2c(CCc3sc(-c4ccc(C(F)(F)F)cc4)nc3C(C)C)noc2cc1OC(C)(C)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 20/20 1.00
PPARD Q03181 18/20 1.00
PPARG P37231 11/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12732556 0.92 PPARA (0.85) PPARAPPARDPPARG
SCHEMBL4034553 0.92 PPARD (0.85) PPARAPPARDPPARG
Fonadelpar SCHEMBL1765984 0.89 PPARD (0.81) PPARAPPARDPPARG
SCHEMBL24658288 0.89 PPARD (0.80) PPARAPPARDPPARG
SCHEMBL30003947 0.89 PPARD (0.80) PPARAPPARDPPARG
SCHEMBL4803438 0.87 PPARD (0.77) PPARAPPARDPPARG
SCHEMBL4025440 0.87 PPARA (0.77) PPARAPPARDPPARG
SCHEMBL30004467 0.87 PPARD (0.76) PPARAPPARDPPARG
SCHEMBL24658290 0.87 PPARD (0.76) PPARAPPARDPPARG
SCHEMBL4034665 0.85 PPARD (0.73) PPARAPPARDPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2464349-A2 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES Cerenis Therapeutics S.A. (FR) 2012-06-20 EP disclosed
WO-2011020001-A9 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES CERENIS THERAPEUTICS S.A. (FR) 2011-05-26 WO disclosed
US-20110092517-A1 Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases Cerenis Therapeutics S.A. & Nippon Chemiphar Co., Ltd. 2011-04-21 US disclosed
WO-2011020001-A2 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES CERENIS THERAPEUTICS S.A. (FR) 2011-02-17 WO disclosed
EP-1445258-B1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA NIPPON CHEMIPHAR CO (JP) 2009-06-24 EP disclosed
US-7402597-B2 Activator of peroxisome proliferator-activated receptor δ NIPPON CHEMIPHAR CO., LTD (JP) 2008-07-22 US disclosed
US-20070027196-A1 Activator of peroxisome proliferator-activated receptor delta SAKUMA SHOGO 2007-02-01 US disclosed
US-7119104-B2 Activator of peroxisome proliferator-activated receptor delta NIPPON CHEMIPHAR, CO., LTD. (JP) 2006-10-10 US disclosed
US-20050096363-A1 Activator of peroxisome proliferator-activated receptor delta NIPPON CHEMIPHAR CO., LTD. (JP) 2005-05-05 US disclosed
EP-1445258-A1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA NIPPON CHEMIPHAR CO., LTD. (JP) 2004-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092517-A1 Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases PPARD, PPARG, PPARA PPARA 3/4885PPARD 1/4885PPARG 2/4885
US-20070027196-A1 Activator of peroxisome proliferator-activated receptor delta PPARA, PPARG, PPARD PPARA 1/4885PPARD 3/4885PPARG 2/4885
US-20050096363-A1 Activator of peroxisome proliferator-activated receptor delta PPARA, PPARG, PPARD PPARA 1/4885PPARD 3/4885PPARG 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.